211 related articles for article (PubMed ID: 37972062)
21. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
22. Development and verification of an immune-related gene prognostic index for gastric cancer.
Zhang C; Liu T; Wang J; Zhang J
Sci Rep; 2022 Sep; 12(1):15693. PubMed ID: 36127384
[TBL] [Abstract][Full Text] [Related]
23. A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma.
Cai Y; Liang X; Zhan Z; Zeng Y; Lin J; Xu A; Xue S; Xu W; Chai P; Mao Y; Song Z; Han L; Xiao J; Song Y; Zhang X
Front Cell Dev Biol; 2021; 9():812422. PubMed ID: 35174170
[No Abstract] [Full Text] [Related]
24. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
25. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
26. The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer.
Liu C; Gao Y; Ni J; Chen S; Hu Q; Wang C; Hu M; Chen M
BMC Cancer; 2022 Jul; 22(1):788. PubMed ID: 35850679
[TBL] [Abstract][Full Text] [Related]
27. CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression.
Gu Y; Wu S; Fan J; Meng Z; Gao G; Liu T; Wang Q; Xia H; Wang X; Wu K
Cell Death Dis; 2024 Jan; 15(1):79. PubMed ID: 38246916
[TBL] [Abstract][Full Text] [Related]
28. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
[TBL] [Abstract][Full Text] [Related]
29. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
Front Immunol; 2022; 13():944286. PubMed ID: 36591255
[TBL] [Abstract][Full Text] [Related]
30. Aspartoacylase suppresses prostate cancer progression by blocking LYN activation.
Weng H; Xiong KP; Wang W; Qian KY; Yuan S; Wang G; Yu F; Luo J; Lu MX; Yang ZH; Liu T; Huang X; Zheng H; Wang XH
Mil Med Res; 2023 Jun; 10(1):25. PubMed ID: 37271807
[TBL] [Abstract][Full Text] [Related]
31. The circadian rhythm key gene
Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
[TBL] [Abstract][Full Text] [Related]
32. Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.
Zhou R; Ma HC; Liu YH; Chen X; Chang XS; Chen YD; Liu LR; Li Y; Zhu YJ; Zhang HB
Exp Biol Med (Maywood); 2022 Aug; 247(16):1447-1465. PubMed ID: 35762414
[TBL] [Abstract][Full Text] [Related]
33. Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition.
Saha A; Zhao S; Kindall A; Wilder C; Friedman CA; Clark R; Georgiou G; Stone E; Kidane D; DiGiovanni J
J Exp Clin Cancer Res; 2023 May; 42(1):119. PubMed ID: 37170264
[TBL] [Abstract][Full Text] [Related]
34. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
[TBL] [Abstract][Full Text] [Related]
35. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
38. Identification and validation of a ferroptosis-related signature for prediction of the prognosis and tumor microenvironment in patients with chromophobe renal cell carcinoma.
Liu S; Yao Y; Hou M; Mei J; Sun L; Zhang G
BMC Cancer; 2023 Nov; 23(1):1079. PubMed ID: 37940859
[TBL] [Abstract][Full Text] [Related]
39. The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer Treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract][Full Text] [Related]
40. Nonferrous Ferroptosis Inducer Manganese Molybdate Nanoparticles to Enhance Tumor Immunotherapy.
Lei H; Li Q; Pei Z; Liu L; Yang N; Cheng L
Small; 2023 Nov; 19(45):e2303438. PubMed ID: 37420331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
